WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
How Microsoft bagged Activision Blizzard
‘Dumb Money’ writers on the GameStop saga
Bonus: Michael Lewis on FTX & Sam Bankman-Fried
FTC versus Amazon
Argentina’s $16bn saga with a US court
Best Of: Why Apple can’t leave China
The push to dominate the battery supply chain
Coming soon: Can AI help us speak to animals?
The Russian Banker, Part 3: Asylum
Bonus: Arm’s race to IPO
The Russian Banker, Part 2: The Whistleblower
The Russian Banker, Part 1: The Raid
Introducing: The Russian Banker
Did Binance miss its chance to rule crypto?
The controversy around share buybacks
How Dubai is reshaping the global oil trade
Institutional investors take to the pitch
A different way to understand the US economy
Macquarie’s grip on global infrastructure
Frances Haugen’s lessons as a Facebook whistleblower
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly